Tetracycline
Achromycin, Bismuth / Metronidazole / Tetracycline, Pylera, Sumycin, Tetracycline, Tetracyn, Tetrex (tetracycline) is a small molecule pharmaceutical. Tetracycline was first approved as Achromycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, bartonella infections, and borrelia infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Achromycin, Sumycin, Tetracycline (discontinued: Achromycin, Actisite, Bristacycline, Cyclopar, Panmycin, Retet, Robitet, Sumycin, Tetracycline, Tetracyn, Tetramed, Tetrex, Topicycline)
CombinationsBismuth subcitrate potassium, metronidazole tetracycline, Bismuth subsalicylate, metronidazole tetracycline (discontinued: Achromycin, Helidac, Tetracyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrocortisone
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACHROMYCIN | Lederle Laboratories | N-050272 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Procaine hydrochloride
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACHROMYCIN | Lederle Laboratories | N-050276 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACHROMYCIN V | Avet Pharmaceuticals | N-050278 RX | 1982-01-01 | 2 products, RLD |
Show 6 discontinued
Bismuth subsalicylate
+
Metronidazole
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HELIDAC | Casper Pharma | N-050719 DISCN | 1996-08-15 | 1 products, RLD |
Hide discontinued
Tetracycline phosphate complex
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TETREX | Bristol Myers Squibb | N-050212 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acnecycline | OTC monograph final | 2011-02-15 |
| apt t3x tetracycline hydrochloride first aid antibiotic | C200263 | 2023-12-01 |
| bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride | NDA authorized generic | 2026-04-13 |
| bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride | ANDA | 2025-11-11 |
| bismuth subsalicylate/metronidazole/tetracycline hydrochloride | ANDA | 2019-11-24 |
| dermacline | OTC monograph final | 2016-11-08 |
| diabecline | OTC monograph final | 2013-07-12 |
| dyabetex | OTC monograph final | 2010-09-05 |
| honestly battleborn first aid for real man | C200263 | 2025-04-07 |
| pylera | New Drug Application | 2026-01-16 |
Show 16 more
Indications
FDA
EMA
Show 45 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB13: Tetracycline
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD02: Lansoprazole, tetracycline and metronidazole
— A02BD08: Bismuth subcitrate, tetracycline and metronidazole
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AA: Tetracycline and derivatives, topical antibiotics
— D06AA04: Tetracycline
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA07: Tetracycline
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA08: Tetracycline and oleandomycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA09: Tetracycline
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA08: Tetracycline
— S03: Ophthalmological and otological preparations
— S03A: Antiinfectives, ophthalmologic and otologic
— S03AA: Antiinfectives
— S03AA02: Tetracycline
Clinical
Clinical Trials
816 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | 1 | 5 | 7 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 1 | 4 | 6 |
| Intraabdominal infections | D059413 | — | — | — | — | 1 | 1 | 4 | 6 |
| Bacterial infections | D001424 | — | A49 | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 1 | — | 1 | 3 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 1 | — | — | 2 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | — | — | 1 |
| Persian gulf syndrome | D018923 | EFO_0007430 | — | — | — | 1 | — | — | 1 |
| Mycoplasma infections | D009175 | — | — | — | — | 1 | — | — | 1 |
| Pleuropneumonia | D011001 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infectious skin diseases | D012874 | — | — | — | — | — | — | 2 | 2 |
| Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 2 | 2 |
| Soft tissue infections | D018461 | — | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | — | R19.7 | — | — | — | — | 1 | 1 |
| Clostridium infections | D003015 | EFO_1000874 | A05.2 | — | — | — | — | 1 | 1 |
| Clostridioides difficile | D016360 | NCBITaxon_1496 | — | — | — | — | — | 1 | 1 |
| Community-acquired infections | D017714 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tetracycline |
| INN | tetracycline |
| Description | Tetracycline is a broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria. It has a role as an antimicrobial agent, an antibacterial drug, an antiprotozoal drug, a protein synthesis inhibitor and an Escherichia coli metabolite. It is a tertiary alpha-hydroxy ketone and a member of tetracyclines. It is a conjugate acid of a tetracycline(1-) and a tetracycline zwitterion. |
| Classification | Small molecule |
| Drug class | antibiotics (tetracycline derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 60-54-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1440 |
| ChEBI ID | 27902 |
| PubChem CID | 54675776 |
| DrugBank | DB00759 |
| UNII ID | F8VB5M810T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Tetracycline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 59,704 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride, Bismuth subsalicylate/metronidazole/tetracycline hydrochloride, Pylera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,749 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use